Blood cancers

Checkpoint blockade shows promise for multiple myeloma

Targeting the T cell immunoglobulin and ITIM domains (TIGIT) immune checkpoint has a future role in the management of multiple myeloma, early research at the QIMR Berghofer Medical Research Institute in Queensland suggests. In a proof of concept study researchers at QIMR have demonstrated that TIGIT expression is upregulated in immune cells in both animal models challenged ...

Already a member?

Login to keep reading.

© 2021 the limbic